Overview

Open-label Study of VTS-270 in Participants With Neurologic Manifestations of Niemann-Pick Type C1

Status:
Active, not recruiting

Trial end date:
2021-11-01

Target enrollment:

Participant gender:

Summary

This is a multicenter, multinational, open-label study of to evaluate the long-term safety, tolerability, and efficacy of VTS-270 (2-hydroxypropyl-β-cyclodextrin) in participants transitioning from Study VTS301 in participants with Neurologic Manifestations of Niemann-Pick Type C1 Disease.

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Mandos LLC
Vtesse, Inc., a Mallinckrodt Pharmaceuticals Company